The Food and Drug Administration has returned dozens of specialized employees participating in food safety, reviewing medical devices and other areas that were demobilized last week, according to more than ten workers who were called again.
The total number of employees who was called out was not immediately clear. But the person familiar with the conversations said that all the 180 -year -old medical department employees who were left would restore their jobs. More than ten workers said through a handful of teams that they had received a call or email who re -employed them; Some have reported that up to dozens of others have been returned in their teams.
The Food and Drug Administration, Mother’s Agency, Ministry of Health and Humanitarian Services did not respond to the requests for suspension.
Workers were separated as part of the Trump administration’s efforts, led by Elon Musk, to significantly reduce the size of the federal government and reduce costs. But the salaries of many food and drug administration employees that were launched were funded by the fees that pay FDA companies, not taxpayers money.
Several re -funded jobs were funded through these types of drawings, but some of these employees were still out of work. Those whose jobs were funded through the cigarette tax, for example, they said they were not called to work during the weekend. These workers reviewed new tobacco products and studied the safety of emerging tobacco products, including electronic cigarettes and devices that heat tobacco but do not burn them.
Friday, The New York Times appeared Accounts of employees who have been developed who have reviewed the safety of surgical robots, cardiovascular systems, and diabetics that implant insulin. All of them returned their jobs from Monday morning.
Advamed, a commercial association for medical devices, has pushed management in a message and in meetings to ensure that workers who review these products have regained their jobs. Industry funds have helped experts of devices review, including experienced doctors in the use of devices. Industry funds are approved periodically in congressional agreements, which also include strict final dates to make approval decisions.
The workers who have spoken, who spoke on the condition of not disclosing their identity because they are afraid of revenge, said that about ten employees from the agency’s chief adviser have regained their jobs, including lawyers who supported the drug policy. About ten dozens are also restored to overseeing cardiovascular devices and 12 others who allow artificial intelligence programs. Others have been called to their jobs to assess food and chemical safety, a priority from the new Minister of Health, Robert F. Kennedy Junior.
In the interviews, the employees who returned on Monday reported a sense of frustration and frustration, but also from the rest to return to work.
Dr. Robert Calif, the FDA Commissioner, during the Biden Administration, called on employee discounts “combating efficiency” because many recent employees have been recruited to fill the agency’s knowledge gaps, including in artificial intelligence and food and chemical safety. He also said that the cuts were not given any consideration of the welfare of the workers.
He said in a text message on Monday.
The workers who were unified were told that their performance “was not enough to justify more employment by the agency.” However, many of the workers who were rejected – returned them and not – said that their performance from the agency was excellent.
Alice Calman The reports contributed.
